Compare AFCG & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFCG | GOSS |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.6M | 83.8M |
| IPO Year | 2020 | 2018 |
| Metric | AFCG | GOSS |
|---|---|---|
| Price | $2.90 | $0.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $4.50 | $4.19 |
| AVG Volume (30 Days) | 93.6K | ★ 17.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | $24,563,601.00 | ★ $48,471,000.00 |
| Revenue This Year | $1,334.03 | N/A |
| Revenue Next Year | $17.33 | $201.64 |
| P/E Ratio | $5.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $0.11 |
| 52 Week High | $5.10 | $3.87 |
| Indicator | AFCG | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 42.89 |
| Support Level | $2.75 | $0.15 |
| Resistance Level | $3.37 | $0.20 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.78 | 56.40 |
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).